An internally controlled, double-blind comparison of the efficacy of onabotulinumtoxinA and abobotulinumtoxinA

Archives of Facial Plastic Surgery

Volumn 13, Issue 6, 2011, Pages 380-386

  Nettar, Kartik D ^a,b   Yu, Kenneth C Y ^a,b   Bapna, Sumit ^a,b   Boscardin, John ^b   Maas, Corey S ^a,b  

^a Maas Clinic   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; MUSCLE RELAXANT AGENT;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CUTANEOUS PARAMETERS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; MALE; MIDDLE AGED; NONPARAMETRIC TEST; ORBIT; PHOTOGRAPHY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; AGED; BOTULINUM TOXINS, TYPE A; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROMUSCULAR AGENTS; ORBIT; PHOTOGRAPHY; SKIN AGING; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 80755148152     PISSN: 15212491     EISSN: 15383660     Source Type: Journal    
DOI: 10.1001/archfacial.2011.37     Document Type: Article

References (13)

1. Maas CS. Botulinum neurotoxins and injectable fillers: minimally invasive management of the aging upper face. Facial Plast Surg Clin North Am. 2006;14(3):241-245. (Pubitemid 44184938)
2. Maas CS, Yu K C Y, Egan KK. Neuromodulators and injectable soft tissue substitutes. In: Papel ID, ed. Facial Plastic and Reconstructive Surgery. 3rd ed. New York, NY: Thieme Medical Publishers; 2009:337-353.
3. Carruthers JD, Carruthers JA. Treatment of glabellar frown lines with C. botulinum - A exotoxin. J Dermatol Surg Oncol. 1992;18(1):17-21.
4. Bikhazi NB, Maas CS. Refinement in the rehabilitation of the paralyzed face using botulinum toxin. Otolaryngol Head Neck Surg. 1997;117(4):303-307. (Pubitemid 27441456)
5. Moy R, Maas C, Monheit G, Huber MB; Reloxin Investigational Group. Longterm safety and efficacy of a new botulinum toxin type A in treating glabellar lines. Arch Facial Plast Surg. 2009;11(2):77-83.
6. Carruthers A, Carruthers J, Hardas B, et al. A validated grading scale for crow's feet. Dermatol Surg. 2008;34(suppl 2):S173-S178.
7. Ascher B, Rzany BJ, Grover R. Efficacy and safety of botulinum toxin type A in the treatment of lateral crow's feet: double-blind, placebo-controlled, doseranging study. Dermatol Surg. 2009;35(10):1478-1486.
8. Monheit G, Carruthers A, Brandt F, Rand R. A randomized, double-blind, placebocontrolled study of botulinum toxin type A for the treatment of glabellar lines: determination of optimal dose. Dermatol Surg. 2007;33(1, special issue):S51-S59. (Pubitemid 46051400)
9. Pickett AM, Hambleton P. Dose standardisation of botulinum toxin. Lancet. 1994;344(8920):474-475.
10. Hambleton P, Pickett AM. Potency equivalence of botulinum toxin preparations. J R Soc Med. 1994;87(11):719. (Pubitemid 24334671)
11. Marion MH, Sheehy M, Sangla S, Soulayrol S. Dose standardisation of botulinum toxin. J Neurol Neurosurg Psychiatry. 1995;59(1):102-103.
12. Brin MF, Blitzer A. Botulinum toxin: dangerous terminology errors. J R Soc Med. 1993;86(8):493-494. (Pubitemid 23226068)
13. Marsden CD. The authors reply: botulinum toxin dangerous terminology errors. J R Soc Med. 1993;86(8):494.